Laura Mendez

Iterion is excited to present new data on Tegavivint at the upcoming AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22–25 in Boston. Our Chief Scientific Officer, Stephen Horrigan, and Senior Director of Translational Research and Non-Clinical Development, Aundrietta Duncan, will share findings highlighting Tegavivint’s first-in-class mechanism and activity in advanced hepatocellular carcinoma (aHCC). Tegavivint, …

Iterion to present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More »

HOUSTON, Feb. 20, 2024 /PRNewswire/ — Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling a Phase 1b/2a clinical trial of its lead molecule, tegavivint, in patients with advanced hepatocellular carcinoma (HCC) that have failed at least …

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments Read More »

Iterion announces collaboration with Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute.

Iterion shares results from collaboration with Cancer Research UK (CRUK)

Results announced from dose escalation study of tegavivint in desmoid tumors.  

Iterion Therapeutics announces presentation of three posters involving research into tegavivint at the AACR 2022 Annual Meeting

Iterion initiates Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.

Children’s Oncology Group Pediatric Early Phase Clinical Trials Network, a National Cancer Institute-supported clinical trials group, sponsors first clinical study for tegavivint in the pediatric population